SGP Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

24.630

Open

24.630

VWAP

22.84

Vol

95.37K

Mkt Cap

755.77M

Low

21.290

Amount

2.18M

EV/EBITDA(TTM)

Total Shares

33.43M

842.27M

EV/OCF(TTM)

P/S(TTM)

SpyGlass Pharma Inc is a United States-based ophthalmic drug delivery company. The Company is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.

Events Timeline

(ET)

2026-03-09

08:10:00

SpyGlass Pharma Reports Positive 12-Month Trial Results for BIM-IOL System

2026-03-03 (ET)

2026-03-03

16:20:00

US Stocks Drop Amid Middle East Tensions; Trump Announces Maritime Trade Security Measures

2026-03-03

11:50:00

Middle East Conflict Escalates, Major Indices Down Nearly 1.5%

2026-03-02 (ET)

2026-03-02

11:30:00

Generate Biomedicines Debuts with 6% Price Increase

News

8.5

03-26seekingalpha

SpyGlass Pharma Reports Q4 Earnings and IPO Details

8.5

03-26Newsfilter

SpyGlass Pharma Completes IPO, Raising $172.5 Million

6.0

03-03Benzinga

Wall Street Analysts Adjust Ratings on Key Stocks

6.5

03-03Benzinga

Wall Street Analysts Adjust Ratings

8.5

03-02renaissancecapital

February IPO Market Review and Outlook

8.5

02-06Barron's

Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes

0 Analyst Rating

Wall Street analysts forecast SGP stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

H.C. Wainwright

Yi Chen

initiated

$37

AI Analysis

2026-03-10

Reason

H.C. Wainwright

Yi Chen

Price Target

$37

AI Analysis

2026-03-10

initiated

Reason

H.C. Wainwright analyst Yi Chen initiated coverage of SpyGlass Pharma with a Buy rating and $37 price target. SpyGlass is a clinical-stage biopharmaceutical company focused on the development of long-acting, sustained drug delivery of approved medicines, the analyst tells investors in a research note. The firm believes the company's bimatoprost solve the issue of patient non-compliance for prescribed topical medications, which could lead to better control of intraocular pressure.

Stifel

initiated

$42

2026-03-03

Reason

Stifel

Price Target

$42

2026-03-03

initiated

Reason

Stifel initiated coverage of SpyGlass Pharma with a Buy rating and $42 price target. The firm says that by combining a known drug, a known procedure, and a known device, SpyGlass' sustained-release drug-delivery BIM-IOL is "poised to capitalize on the ongoing interventional glaucoma secular shift." The BIM-IOL U.S. total addressable market is large at $13B annually, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for SGP

Unlock Now

Valuation Metrics

The current forward P/E ratio for SpyGlass Pharma Inc (SGP.O) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess SpyGlass Pharma Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

Current PE

NaN

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

Current EV/EBITDA

NaN

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

Current PS

NaN

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding SGP

Nt-Comnwlth Super Corp

IOOF Investment Management Limited

Adelante Capital Management LLC

Security Capital Research & Management Incorporated

Lion Global Investors Limited

Trading Trends

People Also Watch

Frequently Asked Questions

What is SpyGlass Pharma Inc (SGP) stock price today?

The current price of SGP is 22.61 USD — it has decreased -10.28

What is SpyGlass Pharma Inc (SGP)'s business?

What is the price predicton of SGP Stock?

Wall Street analysts forecast SGP stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SGP is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is SpyGlass Pharma Inc (SGP)'s revenue for the last quarter?

SpyGlass Pharma Inc revenue for the last quarter amounts to NaN USD, decreased

What is SpyGlass Pharma Inc (SGP)'s earnings per share (EPS) for the last quarter?

SpyGlass Pharma Inc. EPS for the last quarter amounts to USD, decreased

How many employees does SpyGlass Pharma Inc (SGP). have?

SpyGlass Pharma Inc (SGP) has 65 emplpoyees as of March 30 2026.

What is SpyGlass Pharma Inc (SGP) market cap?

Today SGP has the market capitalization of 755.77M USD.

SGP Overview

SGP Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Whales Holding SGP

Trading Trends

People Also Watch

Frequently Asked Questions

What is SpyGlass Pharma Inc (SGP) stock price today?

What is SpyGlass Pharma Inc (SGP)'s business?

What is the price predicton of SGP Stock?

What is SpyGlass Pharma Inc (SGP)'s revenue for the last quarter?

What is SpyGlass Pharma Inc (SGP)'s earnings per share (EPS) for the last quarter?

How many employees does SpyGlass Pharma Inc (SGP). have?

What is SpyGlass Pharma Inc (SGP) market cap?